4896 — K Pharma Income Statement
0.000.00%
Last trade - 00:00Annual income statement for K Pharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 1,000 | 0 |
| Cost of Revenue | ||||
| Gross Profit | — | — | 910 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 228 | 385 | 687 | 844 |
| Operating Profit | -228 | -385 | 313 | -844 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -229 | -391 | 301 | -844 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -229 | -392 | 260 | -846 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -229 | -392 | 260 | -846 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -229 | -392 | 260 | -846 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -19.3 | -32.2 | 26.4 | -72.5 |
| Dividends per Share |